Grazoprevir

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Grazoprevir is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2016. DrugCentral lists 7 molecular targets, including Genome polyprotein, Genome polyprotein and Genome polyprotein. Recorded indications include Chronic hepatitis C.

• Approval status: ofm (first approved 2016 by the FDA).
• Molecular targets: Genome polyprotein, Genome polyprotein, Genome polyprotein and NS3 (7 listed in DrugCentral).
• Indications: Chronic hepatitis C.
• ATC code: J05AP11 (Antivirals for treatment of HCV infections).
• Molecular formula: C38H50N6O9S; molecular weight 766.91 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic hepatitis C

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
Genome polyprotein	—	inhibitor	EC50 12.52
Genome polyprotein	—	inhibitor	EC50 12.40
Genome polyprotein	—	inhibitor	EC50 12.30
Genome polyprotein	NS3	unknown	Ki 10.40
NS3	NS3	unknown	Ki 10.40
NS3 protease	NS3	unknown	IC50 10.15
Genome polyprotein	—	unknown	Ki 9.85

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2016-01-28	FDA	—	MERCK SHARP DOHME

ATC classification

ATC code	Therapeutic hierarchy
J05AP11	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
J05AP54	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pancreas transplant rejection	59.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Grazoprevir is on its molecule page.

• Molecular formula: C₃₈H₅₀N₆O₉S
• Molecular weight: 766.91 g/mol
• CAS number: 1350514-68-9
• InChIKey: OBMNJSNZOWALQB-NCQNOWPTSA-N
• PubChem CID: 44603531

COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3C[C@H]3OC(=O)N[C@H](C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)OC1=N2)C(C)(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Grazoprevir used for?

DrugCentral lists the following indications for Grazoprevir: Chronic hepatitis C.

How does Grazoprevir work?

Its molecular targets in DrugCentral include Genome polyprotein (inhibitor), Genome polyprotein (inhibitor), Genome polyprotein (inhibitor) and NS3.

When was Grazoprevir first approved?

Grazoprevir was first approved by the FDA in 2016.

What is the chemical formula of Grazoprevir?

Grazoprevir has the molecular formula C38H50N6O9S and a molecular weight of 766.91 g/mol.

Sources

• DrugCentral drug card 5081 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2063090 — compound record and bioactivity
• PubChem CID 44603531 — chemical identifiers
• DrugBank DB11575 — drug record
• FDA UNII 4O2AB118LA — substance identity
• DailyMed: FDA labels for Grazoprevir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.